Granules India Limited · NSE:GRANULES
Granules India — Q3 FY19 Earnings Presentation
21 slides from Granules India's earnings presentation, Jan 30, 2019
Slide 1: Cover letter to stock exchanges
(fig GRANULES REGISTERED OFFICE GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub, Madhapur, Hyderabad - 500 081, Telangana, INDIA. Tel: +91 40 30660000, Fax: +91 40 23115145, mai|@granulesindia.com, wwwgranulesindiaicom CIN: L24110TG1991PLC012471 Dated January 30, 2019 To, National Stock Excha
Slide 2: Investor Presentation Q3 FY19
Investor Presentation Q3 FY19 © 2018 Granules India Limited., All Rights Reserved.
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Q3 FY19 Updates
Q3 FY19 Updates 3 © 2018 Granules India Limited., All Rights 3 Reserved.
Slide 5: Q3 Financial Performance Highlights
Q3 Financial Performance Highlights S A L E S F R O M O P E R AT I O N S EBITDA PAT EPS* Rs 632 Crs Rs 119 Crs Rs 60 Crs Rs 9.0 54% over Q3FY18 59% over Q3FY18 72% over Q3FY18 44% over 9MFY18* * Diluted 9M EPS annualised Product Vertical wise – Q3FY19 Geography wise – Q3FY19 Production Details 5,720
Slide 6: About Granules
About Granules 5 © 2018 Granules India Limited., All Rights 5 Reserved.
Slide 7: Granules at a Glance
Granules at a Glance Building Blocks Installed Capacity Regulatory Approvals Business Divisions Global Reach Regulatory Compliance 34,560 TPA of API USFDA, EDQM, EU Core Business 60+ countries Operational Efficiency 285 KL GMP, COFEPRIS, WHO Emerging Business 250+ customers 4,800
Slide 8: Group Structure and Manufacturing Presence
Group Structure and Manufacturing Presence Incorporated in 1991, this is the only listed entity in the group, with 4 operational plants located in Hyderabad Granules India (Jeedimetla, Bonthapally and Gagillapur) and 1 in Vizag Pharma City 1 Granules USA Inc. 100% subsidiary, for front-end marketing
Slide 9: Business Structure – Granules India
Business Structure – Granules India Focus on core products including Auxiliary growth engine to secure the Paracetamol, Metformin HCl, Ibuprofen, future while strengthening the core Guaifenesin and Methocarbamol. Added business Cetrizine and Fexofenadine to the portfolio Growth avenue for diff
Slide 10: Core Business
Core Business Overview Drivers Value Enablers Present across the entire pharmaceutical One of the World’s largest PFI and single site FD facility manufacturing value chain from API to API capacity 34,560 MT, PFI 24,400 TPA & Finished Finished Dosages. Dosages 18 billion Scale DMFs, Dossiers,
Slide 11: Emerging Business: Multi APIs / Onco
Emerging Business: Multi APIs / Onco Overview Drivers Value Enablers Addition of USFDA approved multiproduct manufacturing site enabling scale-up and Multiproduct facility with an installed capacity of 285KL manufacturing of niche APIs through in- Integrated API to FD facility for Oncology hou
Slide 12: US Generics
US Generics Overview Drivers Value Enablers Fully integrated infrastructure from R&D, “Niche products,” hidden opportunities with different manufacturing to marketing enabling layers of complexities “Make in America” Differentiated dosage forms; limited competition Portfolio Complex generics
Slide 13: JVs – Granules Omnichem & Granules Biocause
JVs – Granules Omichem & Granules Biocause Granules Omnichem Overview Drivers Value Enablers 2,500 25% 19.5% 19.1% Granules Biocause, a venture with China High margin opportunity in 2,000 20% based Hubei Biocause operational since CRAMS with manufacturing for 2007. Objective is to enable core in
Slide 14: Core Management Team
Core Management Team Mr. C. Krishna Prasad Mr. Prasad is the Founder of Granules and has three decades of experience in the pharmaceutical industry. In 1984, he set up a Paracetamol manufacturing facility, focused on capital and process efficiency. Pharmaceutical Formulations Intermediates Chairman
Slide 15: Financial Performance
Financial Performance 14 © 2018 Granules India Limited., All Rights 14 Reserved.
Slide 16: Consolidated Metrics
Consolidated Metrics Product Vertical wise Geography wise 6% 5% 8% 33% 38% 39% 10% 12% 11% 18% 21% 19% 28% 24% 25% 24% 22% 24% 39% 38% 37% 39% 42% 38% FY16 FY17 FY18 FY16 FY17 FY18 North America Europe API PFI FD India LATAM ROW # Break up of Revenue as per IND AS © 2018 Granules India Limited., All
Slide 17: Consolidated Financial Overview – Trends
Consolidated Financial Overview – Trends 1,800 1,692 25% Future Value Drivers 1,600 1,383 21.5% 20% 1,400 20.4% 1,435 1,200 17.1% 15% 1,000 Optimal Utilization Rs Cr of Core Business 800 11.5% 10% installed capacities 600 9.0% 7.8% 400 282 309 289 5% 125 165 133 200 0 0% Scale-up of FY16 FY17 FY18 G
Slide 18: Balance Sheet Highlights
Balance Sheet Highlights Net Debt to EBITDA ROCE Asset Turnover (x) 13.4 3.0 1.6 % 11.7 % 1.5 2.6 Mar-18 Sep-18 Mar-18 Sep-18 Mar-18 Sep-18 Net Debt to Equity Return on Equity Cash to Cash Cycle (Days) 16.5 0.7 0.7 % 140 12.0 % 137 Mar-18 Sep-18 Mar-18 Sep-18 Mar-18 Sep-18 © 2018 Granules India Limi
Slide 19: Way Forward
Way Forward 18 © 2018 Granules India Limited., All Rights 18 Reserved.
Slide 20: Way Forward
Way Forward Building Profitable Growth Steady Returns Blocks in Place through Execution to the Stakeholders Integrated platform in place that can Expanding portfolio range with Financial discipline to a key focus address the entire value chain from addition of differentiated and intermediates
Slide 21: For further information, please contact
For further information, please contact: Company Investor Relations contact Christensen IR Sumanta Bajpayee Shivangi Bubna Head - Corporate Finance & IR 040-30663572 022-42150210 sumanta.bajpayee@granulesindia.com sbubna@christensenir.com 532482 GRANULES GRAN:IN GRAN:NS © 2018 Granules India Limited